Multicenter, Randomized, Double Blind, Three-arm Parallel Group Study to Evaluate Efficacy and Safety of Alogliptin and Pioglitazone Combination Therapy on Glucose Control in Type 2 Diabetes Subjects Who Have Inadequate Control With Metformin Monotherapy in Korea
Phase of Trial: Phase IV
Latest Information Update: 11 Feb 2019
Price : $35 *
At a glance
- Drugs Alogliptin (Primary) ; Pioglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms PEAK
- 07 Feb 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 12 Jul 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.